You are currently viewing a new version of our website. To view the old version click .

Pharmaceuticals, Volume 5, Issue 4

April 2012 - 5 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (5)

  • Article
  • Open Access
9 Citations
7,579 Views
7 Pages

16 April 2012

Accelerated sinus rhythm is an important side effect of inhaled salbutamol which is especially harmful in patients with chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). Cross-over, randomized, open label study design. 20...

  • Review
  • Open Access
26 Citations
10,106 Views
15 Pages

5 April 2012

The number of children with mild neurodevelopmental disorders, such as autism, has been recently increasing in advanced countries. This increase is probably caused by environmental factors rather than genetic factors, because it is unlikely that gene...

  • Review
  • Open Access
3 Citations
7,271 Views
14 Pages

Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines

  • Luciana Armaganijan,
  • Dimpi Patel,
  • Cristiano Dietrich and
  • Carlos A. Morillo

5 April 2012

Atrial Fibrillation (AF) is the most common sustained arrhythmia and 1/6 strokes is attributed to AF. The cornerstone of treatment remains maintaining sinus rhythm or appropriate ventricular rate control in addition to prevention of stroke. Oral anti...

  • Review
  • Open Access
93 Citations
15,017 Views
16 Pages

30 March 2012

Biosimilars (or follow-on biologics) are a new class of medicine which enters the market subsequent to a previously approved version. They have demonstrated similarity to innovator biologic products in terms of quality, safety, and efficacy. The EMA...

  • Article
  • Open Access
30 Citations
11,307 Views
14 Pages

28 March 2012

Objective: Shark type II collagen (SCII) is extracted as a glycoprotein from the cartilage of blue shark (Prionace glauca). We aim to confirm the effects of oral tolerance of SCII on inflammatory and immune responses to the ankle joint of rheumatoid-...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmaceuticals - ISSN 1424-8247